Phototoxic dermatoses in pediatric BMT patients receiving voriconazole

Pediatric Blood and Cancer

Volumn 61, Issue 7, 2014, Pages 1325-1328

  Goyal, Rakesh K ^a,b   Gehris, Robin P ^b   Howrie, Denise ^a,c   Cogley, Kayla M ^a   Windreich, Randy M ^a,b   Venkataramanan, Raman ^c  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Allogeneic BMT; Phototoxicity; Voriconazole

Indexed keywords

CORTICOSTEROID; POSACONAZOLE; STEROID; SUNSCREEN; VORICONAZOLE;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLISTER; CHEILITIS; CHILD; DESQUAMATION; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DRY SKIN; ERYTHEMA; FACE ERYTHEMA; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; HYPERPIGMENTATION; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MAJOR CLINICAL STUDY; MALE; MYCOSIS; OUTCOME ASSESSMENT; PAPULOVESICULAR RASH; PHOTOTOXIC DERMATOSIS; PHOTOTOXICITY; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOPORPHYRIA; SCHOOL CHILD; SIDE EFFECT; SKIN CANCER; SKIN MANIFESTATION; SKIN PAIN; SKIN SWELLING; SUN EXPOSURE; SUNBURN; WRINKLE; YOUNG ADULT;

ALLOGENEIC BMT; PHOTOTOXICITY; VORICONAZOLE;

ALLOGRAFTS; ANTIFUNGAL AGENTS; BONE MARROW TRANSPLANTATION; CHILD; FEMALE; HUMANS; MALE; PHOTOSENSITIVITY DISORDERS; PYRIMIDINES; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SUNLIGHT; SUNSCREENING AGENTS; TRIAZOLES;

EID: 84899690998     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24897     Document Type: Article

References (12)

1. Denning DW, Griffiths CE. Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol 2001; 26:648-653.
2. Epaulard O, Leccia MT, Blanche S, et al. Phototoxicity and photocarcinogenesis associated with voriconazole. Med Maladies Infect 2011; 41:639-645.
3. Patel AR, Turner ML, Baird K, et al. Voriconazole-induced phototoxicity masquerading as chronic graft-versus-host disease of the skin in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transpl 2009; 15:370-376.
4. Cowen EW, Nguyen JC, Miller DD, et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010; 62:31-37.
5. Walsh TJ, Driscoll T, Milligan PA, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother 2010; 54:4116-4123.
6. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201-211.
7. Markantonis SL, Katelari A, Pappa E, et al. Voriconazole pharmacokinetics and photosensitivity in children with cystic fibrosis. J Cyst Fibros 2012; 11:246-252.
8. Haylett AK, Felton S, Denning DW, et al. Voriconazole-induced photosensitivity: Photobiological assessment of a case series of 12 patients. Br J Dermatol 2013; 168:179-185.
9. Murayama N, Imai N, Nakane T, et al. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol 2007; 73(12):2020-2026.
10. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Eng J Med 1994; 331:1272-1285.
11. Epaulard O, Villier C, Ravaud P, et al. A multistep voriconazole-related phototoxic pathway may lead to skin carcinoma: Results from a french nationwide study. Clin Infect Dis 2013; 57:e182-e188.
12. Agency EM. Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000387/WC500049756.pdf Accessed November 14, 2013.